about
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriersLarge-scale genotyping identifies 41 new loci associated with breast cancer risk.Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European DescentIdentification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example.Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.Genetic analysis of von Hippel-Lindau disease.Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.MicroRNA related polymorphisms and breast cancer risk.HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriersAssociation of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriersA locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general populationIdentification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer riskAssessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers.BRCA1 Circos: a visualisation resource for functional analysis of missense variants.Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriersAn original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriersMolecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutationsPathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancerA nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patientsOvarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.Difference in CXCR4 expression between sporadic and VHL-related hemangioblastoma.Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry.No evidence that GATA3 rs570613 SNP modifies breast cancer risk.Attitude towards pre-implantation genetic diagnosis for hereditary cancer.Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.Tissue selectivity in multiple endocrine neoplasia type 1-associated tumorigenesis.Uptake of prenatal diagnostic testing for retinoblastoma compared to other hereditary cancer syndromes in the NetherlandsPrimary hyperparathyroidism in MEN1 patients: a cohort study with longterm follow-up on preferred surgical procedure and the relation with genotype.The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium.Quality and quantity of DNA isolated from frozen urine in population-based research.Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? results from a randomized clinical trial.Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping.Association analysis identifies 65 new breast cancer risk loci.
P50
Q21144874-91EBEDDD-838E-481B-BCC1-6A5CAD2E3182Q29416989-A77C2F63-E0A0-455B-B1D7-7095BE4C98C2Q30000080-D906EEDF-3F76-472A-BF2D-753477058DA1Q30252854-C1A66429-F082-42F9-8ED9-5DB11D4CCCC4Q33475933-ACD4E042-BE60-4269-BDFC-5217AA90E3C8Q34081324-2624E939-F956-4AD3-B9B1-6562665D72D1Q34098432-4EA9B7B3-A06A-4A9F-B33A-7A5A2EFDCDA5Q34394665-85956322-8D55-46DF-A98A-755162CAB2E2Q34497352-8325A9BC-3ECF-44A9-B1AE-1EB28737E8F0Q34586591-AD8D751C-A595-469D-8DF7-E3B0700E010DQ34801008-FAEF4467-DB51-44FB-B219-4A778062DD83Q35089479-685E968F-C310-41F6-80A6-809DA56A2DABQ35102646-2C8CFF73-6D5D-4BEB-BE15-95E6C3C8062CQ35242849-15731DAB-884A-462A-AF1E-9C95911C63E6Q35350825-1AE47298-CEBE-4DB3-9A3C-55ABD9B9E5D0Q35523236-C29AE298-EB61-453E-9165-985EBEC1AE44Q35618307-96C77EDA-ECDF-47FB-881A-ED4109958AF3Q35676798-35F0A7CB-5C33-4252-9C91-6524C47AAF03Q35737888-C8199CD9-7B2E-48F5-B0EB-7C15E05B3552Q35889575-1C5770DF-C89D-489D-B96B-0E0C4853C9EBQ35996692-E60FA042-B2ED-4228-ADC3-047870DB9D35Q36152991-DBEA4AF6-3D43-46E5-AAFB-54FCB488A10AQ36178189-405C044B-C8B8-4794-BA28-7AE571831DC5Q36192096-7E951C8B-0E86-44C3-95DB-57EDD82B2ADBQ36280191-BA381890-5A0C-4AEB-A041-74D4B484D9E3Q36839777-6A781DE7-4969-4EC1-98DF-8B6FE3BA8F02Q36897003-478ACD16-D093-4F8D-9F27-9B0F0EBB960DQ37231081-483E8549-E734-461A-8711-451F18E40E59Q37268494-32A56A91-D8B3-497F-82CD-C14F57DBE8E1Q37308596-E0898563-5A3F-4FEC-93B3-F07ABA6DB7F8Q37407200-D05AE7D4-3CD3-4396-B6D9-851205EC658AQ37434133-D792F415-7100-4AC5-8244-0D8FF4B37329Q37572229-62399724-AEEF-4CCB-ACD3-DC77B613CDDAQ37710174-E1891F33-887C-40D8-AD3F-668C41197CA5Q37999297-9AD94E29-F686-4A50-A66E-0D26652AC90FQ38793676-930D2D7F-981D-4661-A51F-4438BC39B1CBQ40640563-D4A7FCE8-BA52-4524-ABF8-103D5C098093Q41024301-72A11DD1-B1CA-4078-8A6B-6CF31DD28287Q42199595-EE03469C-C49A-439A-A5D4-BDF711F5CE5CQ45979098-2253BB41-5911-4321-AE30-96A2671B5E5F
P50
description
researcher, ORCID id # 0000-0002-0018-1089
@en
wetenschapper
@nl
name
Rob B van der Luijt
@ast
Rob B van der Luijt
@en
Rob B van der Luijt
@es
Rob B van der Luijt
@nl
type
label
Rob B van der Luijt
@ast
Rob B van der Luijt
@en
Rob B van der Luijt
@es
Rob B van der Luijt
@nl
altLabel
Rob van der Luijt
@en
prefLabel
Rob B van der Luijt
@ast
Rob B van der Luijt
@en
Rob B van der Luijt
@es
Rob B van der Luijt
@nl
P106
P31
P496
0000-0002-0018-1089